Dan Van Fleet advises clients on a full spectrum of bespoke and complex financing transactions.
Dan represents companies and lenders, as well as venture capital, private equity, and other private capital firms, in debt and debt-like hybrid financings, particularly in the technology and life sciences industries.
He leverages a commercial perspective and creative approach to provide clients with innovative and effective funding solutions. A trusted strategic advisor, Dan regularly advises companies on their highest-stakes financing transactions involving:
Growth debt, including venture, structured, royalty, and lower middle market
Private capital, private equity, growth equity, and leveraged financings, including acquisitions, add-ons, and refinancings
Asset-based transactions, including IP-backed, recurring revenue, accounts receivable, inventory, data center, and equipment financings
Structured equity and pre-IPO financings
Dan previously served on Latham’s Training and Career Enhancement Committee (TACE) and has been recognized within the firm as an excellent supervisor and leading supporter of recruiting and knowledge management efforts. He is an ally member of the Latham’s Hispanic/Latin American Lawyers Group.
He also serves on Stanford’s Bing Overseas Study Program Advisory Council and the Duke Law Alumni Association Board of Directors.
Experience
Technology
Dan has advised on a variety of debt transactions in the technology industry, including those involving digital assets, cryptocurrency, Web3, cloud services, artificial intelligence (AI), and agtech, including:
Appodeal
Axios
Bright Machines
Canva
EasyPost
Examity
FUBOTV INC.
Inevitable Tech Inc
ironSource
Kandji
Nanosys
Owlet
Spot AI
Tarana Wireless
Life Sciences
Dan has advised on a variety of debt transactions in the healthcare and life sciences industries, including those involving medical device manufacturers, and pharmaceutical and biotech companies, including:
Alignment Healthcare
ATAI Life Sciences
BridgeBio
Centrexion
Coherus
Corium
Everly Health
KSQ Therapeutics
Neurelis
Phathom Pharmaceuticals
scPharmaceuticals
Sight Sciences
Venture Capital, Private Equity, Private Capital and Asset Managers
Dan regularly represents venture capital. private equity and other private capital firms in connection with private and public investments, acquisitions, and divestitures, including:
8VC
Blue Owl Credit Advisors
Flagship Pioneering
Golub Capital
Hercules Capital
Kennedy Lewis Investment Management
Khosla Ventures
Marathon Capital
North Haven Tactical Fund
Blue Owl Capital
SLR Investment Corp.
Trinity Capital Investments
Qualifications
Bar Qualification
California
New York
Education
JD in Education, Duke University School of Law, 2009 Editor, Duke Law Journal and Duke Law & Technology Review
Firm honored by Law360 for advising startups, financial institutions, VCs, digital asset and Web3 participants, and corporations on their most innovative and complex transactions, investigations, litigation, and regulatory matters.
Firm represents leading unicorn consumer loyalty technology company on debt and customer acquisition flow facilities supporting the company’s continued growth.
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.